openPR Logo
Press release

Idiopathic Pulmonary Fibrosis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

12-08-2022 01:12 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Idiopathic Pulmonary Fibrosis Pipeline Drugs and Companies

Idiopathic Pulmonary Fibrosis pipeline constitutes 80+ key companies continuously working towards developing 80+ Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Idiopathic Pulmonary Fibrosis Overview
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by thickening, stiffening and scarring (fibrosis) of tissue within the lungs. Affected individuals develop shortness of breath and progressive lung disease. IPF is classified as a form of idiopathic interstitial pneumonia, which is a group of lung diseases that damage the lungs in a similar manner and occur due to unknown causes. This group of disorders is also known as diffuse parenchymal lung diseases.

"Idiopathic Pulmonary Fibrosis Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Idiopathic Pulmonary Fibrosis Market.

The Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report: https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

• Companies across the globe are diligently working toward developing novel Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years. Idiopathic Pulmonary Fibrosis Key players such as - Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche, and others, are developing therapies for the Idiopathic Pulmonary Fibrosis treatment
• Idiopathic Pulmonary Fibrosis Emerging therapies such as - DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, and others are expected to have a significant impact on the Idiopathic Pulmonary Fibrosis market in the coming years.
• 2020, FibroGen initiated a Zephyrus II: A Phase III, randomized, double-blind, placebo-controlled
• efficacy and safety study of Pamrevlumab in subjects with Idiopathic Pulmonary Fibrosis (IPF).

Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment
• Idiopathic Pulmonary Fibrosis Assessment by Product Type
• Idiopathic Pulmonary Fibrosis By Stage and Product Type
• Idiopathic Pulmonary Fibrosis Assessment by Route of Administration
• Idiopathic Pulmonary Fibrosis By Stage and Route of Administration
• Idiopathic Pulmonary Fibrosis Assessment by Molecule Type
• Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight's Idiopathic Pulmonary Fibrosis Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:
• DUB program: USP30 Inhibitor: Mission Therapeutics
• LTI-03: Lung Therapeutics
• TD-1058: Theravance Biopharma
• PLN-74809: Pliant Therapeutics
• C21: Vicore Pharma
• GB0139: Galecto Biotech
• Pamrevlumab: FibroGen
• PRM-151: Roche

Get a Free Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis Pipeline Assessment- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Idiopathic Pulmonary Fibrosis Pipeline Analysis:
The Idiopathic Pulmonary Fibrosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Idiopathic Pulmonary Fibrosis treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis Treatment.
• Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Idiopathic Pulmonary Fibrosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Idiopathic Pulmonary Fibrosis therapies at:
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of Idiopathic Pulmonary Fibrosis Pipeline Drug Insight
• Coverage: Global
• Key Idiopathic Pulmonary Fibrosis Companies: Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche, and others
• Key Idiopathic Pulmonary Fibrosis Therapies: DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, and others
• Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies
• Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers

Request for Sample PDF Report for Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Idiopathic Pulmonary Fibrosis Report Introduction
2 Idiopathic Pulmonary Fibrosis Executive Summary
3 Idiopathic Pulmonary Fibrosis Overview
4 Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment
5 Idiopathic Pulmonary Fibrosis Pipeline Therapeutics
6 Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)
7 Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)
8 Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)
9 Idiopathic Pulmonary Fibrosis Preclinical Stage Products
10 Idiopathic Pulmonary Fibrosis Therapeutics Assessment
11 Idiopathic Pulmonary Fibrosis Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Idiopathic Pulmonary Fibrosis Key Companies
14 Idiopathic Pulmonary Fibrosis Key Products
15 Idiopathic Pulmonary Fibrosis Unmet Needs
16 Idiopathic Pulmonary Fibrosis Market Drivers and Barriers
17 Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion
18 Idiopathic Pulmonary Fibrosis Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis drugs and therapies- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Idiopathic Pulmonary Fibrosis Market https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Idiopathic Pulmonary Fibrosis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Idiopathic Pulmonary Fibrosis Epidemiology https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Idiopathic Pulmonary Fibrosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Idiopathic Pulmonary Fibrosis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here

News-ID: 2840844 • Views: 296

More Releases from DelveInsight Business Research

Factor Xa Inhibitor Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Factor Xa Inhibitor Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Factor Xa Inhibitor, historical and forecasted epidemiology as well as the Factor Xa Inhibitor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Factor Xa Inhibitor market report provides current treatment practices, emerging drugs, Factor Xa Inhibitor market share of the individual therapies, and current and
Diabetes Insipidus Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Diabetes Insipidus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Diabetes Insipidus, historical and forecasted epidemiology as well as the Diabetes Insipidus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Diabetes Insipidus market report provides current treatment practices, emerging drugs, Diabetes Insipidus market share of the individual therapies, and current and forecasted Diabetes Insipidus market size
Goitre Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Goitre Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Goitre, historical and forecasted epidemiology as well as the Goitre market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Goitre market report provides current treatment practices, emerging drugs, Goitre market share of the individual therapies, and current and forecasted Goitre market size from 2019 to 2032, segmented by
Fibrocystic Breast Condition Market to Witness Growth by 2032, Estimates DelveIn …
DelveInsight's "Fibrocystic Breast Condition Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Fibrocystic Breast Condition, historical and forecasted epidemiology as well as the Fibrocystic Breast Condition market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Fibrocystic Breast Condition market report provides current treatment practices, emerging drugs, Fibrocystic Breast Condition market share of the individual therapies, and current

All 5 Releases


More Releases for Idiopathic

Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry. The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,
Idiopathic Membranous Nephropathy Treatment Market to Witness Significant Growth …
Idiopathic membranous nephropathy a glomerular disease usually of abrupt onset and associated with the nephrotic syndrome. Membranous nephropathy occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria). R&D in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic membranous nephropathy treatment market. In
Global Idiopathic Scoliosis Treatment Market Size by Type (Infantile Idiopathic, …
Global Idiopathic Scoliosis Treatment‎‎‎‎‎‎‎ Market Research report provides vital information related to the overall market and forecast from 2019 to 2026. This report includes the in-depth analysis of market size, share, growth, trends and regional demand and top layers the Idiopathic Scoliosis Treatment‎‎‎‎‎‎‎ Market. The major players dominating the market are focused upon throughout the by analyzing their revenue, their business summary, product segmentation along with the latest developments. Get Sample
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market As per the findings of research, it
Juvenile Idiopathic Arthritis Therapeutics Market
JIA is also known as juvenile idiopathic arthritis and is the most common inflammatory arthritis of childhood, musculoskeletal pain is a common symptom in childhood and is usually benign and self-resolving. JIA is affected to children who are under age 17. Recognizing rare but treatable causes, including inflammatory, malignant and infectious etiologies, remains a constant challenge. According to the American College of Rheumatology, Juvenile idiopathic arthritis affects one in 1000
Chronic Idiopathic Constipation Market Research Report 2024
Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipation